WEL Substance Profile
Manganese — Workplace Exposure Limit Change
CAS: 7439-96-5 | Notation: Inhalable fraction
Current WES
1
mg/m³
New WEL (Dec 2026)
0.02
mg/m³
Change
-98%
reduction
Health Effects
Chronic manganese exposure causes manganism, a progressive neurological condition with symptoms resembling Parkinson's disease including tremors, difficulty walking, facial muscle rigidity, and cognitive impairment. Early symptoms include fatigue, headache, muscle cramps, and mood changes that are frequently misdiagnosed. Manganese accumulates in the brain's basal ganglia, and neurological damage is largely irreversible once established. Reproductive toxicity has also been demonstrated, with reduced fertility observed in exposed workers. Respiratory effects include chemical pneumonitis from acute inhalation of manganese fume and chronic inflammatory changes in the lungs from prolonged exposure to manganese dust.
Where Exposure Occurs
What to Do Now
Monitoring Method
Personal air sampling using a calibrated sampling pump with IOM inhalable sampler and mixed cellulose ester filter. Analysis by ICP-MS or ICP-OES after acid digestion. Sampling duration should cover a full shift to capture time-weighted average exposure. Static monitoring may supplement personal sampling to characterise spatial exposure patterns.
Affected Industries
Measure exposure against the right limit
OH Consultant designs and runs personal exposure monitoring for manganese and inorganic manganese compounds, reviewed by a Certified Industrial Hygienist, and reports results against the limit that applies to your site, whether the 1 December 2026 WHS WEL or a mine-specific limit.
Request a sampling proposal